Synthesis of a new series of 4-chloro-2-mercapto-5-methylbenzenesulfonamide derivatives with potential antitumor activity
摘要:
The syntheses of S-(5-chloro-4-methyl-2-sulfamoylptienyl)alkanethio (or benzothio)hydrazonates (3a-3o) and potassium S-(5-chloro-2-cyanoamidatesulfonyl-4-methylphenyl)alkanethio (or benzothio)hydrazonates (4-10) are described. The compounds 3e, 3i-3o, 7 and 8 were screened at the National Cancer Institute (NCI) for their activities against a panel of 59 tumor cell lines and relationships between Structure and antitumor activity in vitro are discussed. The Compounds 3e, 3j, 3l-3o and 7 exhibited reasonable activity against numerous human tumor cell lines. The prominent compound 3l showed significant activity against some cell lines of leukemia (SR), melanoma (SK-MEL-5), CNS cancer (SF-539), ovarian cancer (OVCAR-3, OVCAR-4) and breast cancer (MDA-MB-231/ACTT) (GI(50) values in the range, 0.3-0.9 muM). Furthermore, compound 8 exhibited the high selectivity against renal cancer (A498) cells (GI(50) < 0.01 muM, TGI = 2.3 muM and LC50 = 35.7 muM). (C) 2003 Elsevier SAS. All rights reserved.
Synthesis of a new series of 4-chloro-2-mercapto-5-methylbenzenesulfonamide derivatives with potential antitumor activity
作者:Jarosław Sławiński
DOI:10.1016/j.ejmech.2003.09.013
日期:2004.2
The syntheses of S-(5-chloro-4-methyl-2-sulfamoylptienyl)alkanethio (or benzothio)hydrazonates (3a-3o) and potassium S-(5-chloro-2-cyanoamidatesulfonyl-4-methylphenyl)alkanethio (or benzothio)hydrazonates (4-10) are described. The compounds 3e, 3i-3o, 7 and 8 were screened at the National Cancer Institute (NCI) for their activities against a panel of 59 tumor cell lines and relationships between Structure and antitumor activity in vitro are discussed. The Compounds 3e, 3j, 3l-3o and 7 exhibited reasonable activity against numerous human tumor cell lines. The prominent compound 3l showed significant activity against some cell lines of leukemia (SR), melanoma (SK-MEL-5), CNS cancer (SF-539), ovarian cancer (OVCAR-3, OVCAR-4) and breast cancer (MDA-MB-231/ACTT) (GI(50) values in the range, 0.3-0.9 muM). Furthermore, compound 8 exhibited the high selectivity against renal cancer (A498) cells (GI(50) < 0.01 muM, TGI = 2.3 muM and LC50 = 35.7 muM). (C) 2003 Elsevier SAS. All rights reserved.